Emerging hotspots highlighted tumor-associated macrophages and STAT3-centered signaling as key drivers of immune suppression and therapeutic resistance.<h4>Conclusion</h4>Research on ovarian cancer immune evasion is expanding quickly and is shifting toward actionable targets and combination strategies. This evidence concerns the gene STAT3 and ovarian carcinoma.